Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections

Bibliography

• Fisher JF, Meroueh SO, Mobashery S. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev 2005;105:395-424
   PubMed Web of Science ®Google Scholar
• Parker RH, Eggleston M. Beta-lactamase inhibitors: another approach to overcoming antimicrobial resistance. Infect Control 1987;8:36-40
   PubMedGoogle Scholar
• Williams JD. Beta-lactamases and beta-lactamase inhibitors. Int J Antimicrob Agents 1999;12(Suppl 1):S3-7; discussion S26-27
   PubMed Web of Science ®Google Scholar
• Fu KP, Neu HC. Comparative inhibition beta-lactamases by novel beta-lactam compounds. Antimicrob Agents Chemother 1979;15:171-6
   PubMed Web of Science ®Google Scholar
• Retsema JA, English AR, Girard A, et al. Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection. Rev Infect Dis 1986;8(Suppl 5):S528-34
   PubMedGoogle Scholar
• Lees L, Milson JA, Knirsch AK, et al. Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use. Rev Infect Dis 1986;8(Suppl 5):S644-50
   PubMedGoogle Scholar
• Lode HM. Rational antibiotic therapy and the position of ampicillin/sulbactam. Int J Antimicrob Agents 2008;32:10-28
   PubMed Web of Science ®Google Scholar
• Campoli-Richards DM, Brogden RN. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs 1987;33:577-609
   PubMed Web of Science ®Google Scholar
• Hj RO, Bradbrook ID, Morrison PJ, et al. Pharmacokinetics and bioavailability of sultamicillin estimated by high performance liquid chromatography. J Antimicrob Chemother 1983;11:435-45
   PubMed Web of Science ®Google Scholar
• Lode H, Hampel B, Bruckner G, et al. The pharmacokinetics of sultamicillin. APMIS Suppl 1989;5:17-22
   PubMedGoogle Scholar
• Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis 1986;8(Suppl 5):S503-11
   PubMedGoogle Scholar
• Nahata MC, Vashi VI, Swanson RN, et al. Pharmacokinetics of ampicillin and sulbactam in pediatric patients. Antimicrob Agents Chemother 1999;43:1225-9
   PubMed Web of Science ®Google Scholar
• Betrosian AP, Frantzeskaki F, Xanthaki A, et al. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 2007;39:38-43
   PubMed Web of Science ®Google Scholar
• Foulds G, Stankewich JP, Marshall DC, et al. Pharmacokinetics of sulbactam in humans. Antimicrob Agents Chemother 1983;23:692-9
   PubMed Web of Science ®Google Scholar
• Hampel B, Lode H, Bruckner G, et al. Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers. Drugs 1988;35(Suppl 7):29-33
   PubMed Web of Science ®Google Scholar
• Foulds G, McBride TJ, Knirsch AK, et al. Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis. Antimicrob Agents Chemother 1987;31:1703-5
   PubMed Web of Science ®Google Scholar
• Meier H, Springsklee M, Wildfeuer A. Penetration of ampicillin and sulbactam into human costal cartilage. Infection 1994;22:152-5
   PubMed Web of Science ®Google Scholar
• Emmerson AM, Cox DA, Lees LJ. Pharmacokinetics of sulbactam and ampicillin following oral administration of sultamicillin with probenecid. Eur J Clin Microbiol 1983;2:340-4
   PubMedGoogle Scholar
• Blackwell BG, Leggett JE, Johnson CA, et al. Ampicillin and sulbactam pharmacokinetics and pharmacodynamics in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1990;10:221-6
   PubMed Web of Science ®Google Scholar
• Ginsburg CM, McCracken GH Jr, Olsen K, et al. Pharmacokinetics and bactericidal activity of sultamicillin in infants and children. J Antimicrob Chemother 1985;15:345-51
   PubMed Web of Science ®Google Scholar
• Patterson JE, Farrel P, Zervos MJ. Time-kill kinetic studies of ampicillin/sulbactam for beta-lactamase-producing enterococci. Diagn Microbiol Infect Dis 1991;14:495-9
   PubMed Web of Science ®Google Scholar
• Drusano G. Pharmacokinetic optimisation of ß-lactams for the treatment of ventilator-associated pneumonia. Eur Respir Rev 2007;16:45-9
   Google Scholar
• Prabhakaran K, Harris EB, Randhawa B. Postantibiotic effect of ampicillin/sulbactam against mycobacteria. Microbios 1999;99:113-22
   PubMedGoogle Scholar
• Spivey JM. The postantibiotic effect. Clin Pharm 1992;11:865-75
   PubMedGoogle Scholar
• Chow JW, Satishchandran V, Snyder TA, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART). Surg Infect (Larchmt) 2005;6:439-48
   PubMedGoogle Scholar
• Werner H, Heizmann W, Heilmann F. The effect of a combination of ampicillin and sulbactam against clinical isolates of anaerobic bacteria. Int J Antimicrob Agents 1996;6(Suppl):S27-30
   PubMed Web of Science ®Google Scholar
• Ngeow YF, Ramachandran S, Cheong YM. Treatment of gonorrhea with sulbactam/ampicillin. Sex Transm Dis 1991;18:192-4
   PubMed Web of Science ®Google Scholar
• Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002;8:144-53
   PubMed Web of Science ®Google Scholar
• Sandanayaka VP, Prashad AS. Resistance to beta-lactam antibiotics: structure and mechanism based design of beta-lactamase inhibitors. Curr Med Chem 2002;9:1145-65
   PubMed Web of Science ®Google Scholar
• Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and b-lactam resistance. FEMS Microbiol Rev 2008;32:361-85
   PubMed Web of Science ®Google Scholar
• Reguera JA, Baquero F, Perez-Diaz JC, et al. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli. J Antimicrob Chemother 1991;27:569-75
   PubMed Web of Science ®Google Scholar
• Georgopapadakou NH. Beta-lactamase inhibitors: evolving compounds for evolving resistance targets. Expert Opin Investig Drugs 2004;13:1307-18
   PubMed Web of Science ®Google Scholar
• Felmingham D, White AR, Jacobs MR, et al. The Alexander Project: the benefits from a decade of surveillance. J Antimicrob Chemother 2005;56(Suppl S2):ii3-21
   PubMed Web of Science ®Google Scholar
• Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007;20:368-89
   PubMed Web of Science ®Google Scholar
• Liu CY, Huang YT, Liao CH, et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 2008;52:3161-8
   PubMed Web of Science ®Google Scholar
• Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007;51:1649-55
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005
   PubMed Web of Science ®Google Scholar
• Giamarellou H. Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2005;11(Suppl 4):1-16
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86
   PubMed Web of Science ®Google Scholar
• Wenzel M, Wildfeuer A, Gutsche F. Pharmacokinetics of ampicillin/sulbactam in patients undergoing colorectal surgery: measurements in serum, the colonic wall and in tissue at the incision site. Int J Antimicrob Agents 1996;6(Suppl):S35-9
   PubMed Web of Science ®Google Scholar
• Acquarolo A, Urli T, Perone G, et al. Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study. Intensive Care Med 2005;31:510-6
   PubMed Web of Science ®Google Scholar
• Chang ST, Chung HY, Pai SD, et al. Sulbactam/ampicillin followed by oral treatment with sultamicillin for medical and surgical infections. Diagn Microbiol Infect Dis 1989;12(Suppl 4):S175S-8
   Google Scholar
• Hara K, Kobayashi H. Sultamicillin experiences in the field of internal medicine. APMIS Suppl 1989;5:51-6
   PubMedGoogle Scholar
• Airede AI, Jalo I, Weerasinghe HD, et al. Observations on oral Sultamicillin/Unasyn CP-45 899 therapy of neonatal infections. Int J Antimicrob Agents 1997;8:103-7
   PubMed Web of Science ®Google Scholar
• Ferreira JB, Rapoport PB, Sakano E, et al. Efficacy and safety of Sultamicillin (Ampicillin/Sulbactam) and Amoxicillin/Clavulanic acid in the treatment of upper respiratory tract infections in adults–an open-label, multicentric, randomized trial. Braz J Otorhinolaryngol 2006;72:104-11
   PubMedGoogle Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Resp Crit Care Med 2005;171:388-416
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. practice guidelines for the diagnosis and management of skin and soft tissue infections. Clin Infect Dis 2005;41:1373-406
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewing S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur R J 2005;26:1138-80
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2006. MMWR 2006;55:RR-11
   Google Scholar
• Federspil P, Grunbacher G, Lejdeborn L, et al. Sultamicillin versus amoxicillin in the treatment of tonsillitis and pharyngitis: a European multicenter study. APMIS Suppl 1989;5:45-50
   PubMedGoogle Scholar
• Nicoletti G, Speciale A, Caccamo F, et al. Sulbactam/ampicillin in the treatment of otitis and sinusitis. J Int Med Res 1991;19(Suppl 1):29A-35A
   PubMed Web of Science ®Google Scholar
• Alvart R. An open multicentre study to compare the efficacy and safety of sultamicillin with that of cefuroxime axetil in acute ear nose and throat infections in adults. J Int Med Res 1992;20(Suppl 1):53A-61A
   PubMed Web of Science ®Google Scholar
• Topuz B, Katircioglu O, Bayramoglu I, et al. Low dose sultamicillin in acute sinusitis. Infez Med 2002;10:45-8
   PubMedGoogle Scholar
• Kaleida PH, Bluestone CD, Blatter MM, et al. Sultamicillin (ampicillin-sulbactam) in the treatment of acute otitis media in children. Pediatr Infect Dis 1986;5:33-8
   PubMedGoogle Scholar
• Rodriguez WJ, Khan WH, Sait T, et al. Sultamicillin (sulbactam/ampicillin) versus amoxycillin in the treatment of acute otitis media in children. J Int Med Res 1990;18(Suppl 4):78D-84D
   PubMed Web of Science ®Google Scholar
• Raillard P, Kose G, Ozkan H, et al. Low-dose sultamicillin oral suspension in the treatment of mild to moderate paediatric infections in Turkey. J Int Med Res 1992;20(Suppl 1):12A-23A
   PubMed Web of Science ®Google Scholar
• Geckler RW. A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract. Clin Ther 1994;16:662-72
   PubMed Web of Science ®Google Scholar
• Jauregui L, Minns P, Hageage G. A comparison of ampicillin/sulbactam versus cefotaxime in the therapy of lower respiratory tract infections in hospitalized patients. J Chemother 1995;7:153-6
   PubMed Web of Science ®Google Scholar
• Schwigon CD, Gabor M, Hartmann J, et al. Which antibiotic is better for the treatment of infections of the lower respiratory tract? Int J Antimicrob Agents 1996;6(Suppl):S73-7
   PubMed Web of Science ®Google Scholar
• Schwigon CD, Cuhorst R, Gabor M, et al. Comparison of sulbactam/ampicillin and cefuroxime in infections of the lower respiratory tract: results of a prospective, randomized and comparative study. Int J Antimicrob Agents 1996;6(Suppl):S67-72
   PubMed Web of Science ®Google Scholar
• McKinnon PS, Neuhauser MM. Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections. Pharmacotherapy 1999;19:724-33
   PubMed Web of Science ®Google Scholar
• Allewelt M, Schuler P, Bolcskei PL, et al. Ampicillin + sulbactam vs clindamycin +/- cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect 2004;10:163-70
   PubMed Web of Science ®Google Scholar
• Kadowaki M, Demura Y, Mizuno S, et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest 2005;127:1276-82
   PubMed Web of Science ®Google Scholar
• Yanagihara K, Fukuda Y, Seki M, et al. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. Intern Med 2006;45:995-9
   PubMed Web of Science ®Google Scholar
• Ott SR, Allewelt M, Lorenz J, et al. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008;36:23-30
   PubMed Web of Science ®Google Scholar
• Wood GC, Hanes SD, Croce MA, et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34:1425-30
   PubMed Web of Science ®Google Scholar
• Betrosian AP, Frantzeskaki F, Xanthaki A, et al. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 2008;56:432-6
   PubMed Web of Science ®Google Scholar
• Williams D, Perri M, Zervos MJ. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia. Eur J Clin Microbiol Infect Dis 1994;13:293-8
   PubMed Web of Science ®Google Scholar
• Yellin AE, Heseltine PN, Berne TV, et al. The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985;161:303-7
   PubMedGoogle Scholar
• Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 1993;217:115-21
   PubMed Web of Science ®Google Scholar
• A randomized controlled trial of ampicillin plus sulbactam vs. gentamicin plus clindamycin in the treatment of intraabdominal infections: a preliminary report. Study Group of Intraabdominal Infections. Rev Infect Dis 1986;8(Suppl 5):S583-8
   PubMedGoogle Scholar
• Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections–a review on randomised clinical trials. Eur J Med Res 2001;6:277-91
   PubMed Web of Science ®Google Scholar
• Wilson SE, Turpin RS, Hu XH, et al. Does initial choice of antimicrobial therapy affect length of stay for patients with complicated intra-abdominal infections? Am Surg 2005;71:816-20
   PubMed Web of Science ®Google Scholar
• Dajani A. Use of ampicillin/sulbactam and sultamicillin in pediatric infections: a re-evaluation. J Int Med Res 2001;29:257-69
   PubMed Web of Science ®Google Scholar
• Kanra G. Experience with ampicillin/sulbactam in severe infections. J Int Med Res 2002;30(Suppl 1):20A-30A
   PubMed Web of Science ®Google Scholar
• Collins MD, Dajani AS, Kim KS, et al. Comparison of ampicillin/sulbactam plus aminoglycoside vs. ampicillin plus clindamycin plus aminoglycoside in the treatment of intraabdominal infections in children. The Multicenter Group. Pediatr Infect Dis J 1998;17 (Suppl 3):S15-18; discussion S20-11
   PubMed Web of Science ®Google Scholar
• Kawada Y. Sultamicillin in the treatment of urinary tract infections. APMIS Suppl 1989;5:63-7
   PubMedGoogle Scholar
• Schutz W. Efficacy and safety of sultamicillin (750 mg bid) compared with amoxycillin/clavulanate (625 mg tid) in patients with umcomplicated urinary tract infections. Int J Antimicrob Agents 1996;6(Suppl):S55-9
   PubMed Web of Science ®Google Scholar
• Naber KG, Wittenberger R. Sultamicillin versus trimethoprim/sulfamethoxazole in the treatment of urinary tract infections. APMIS Suppl 1989;5:57-62
   PubMedGoogle Scholar
• Chan JC. Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology. Adv Ther 1995;12:139-46
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910
   PubMed Web of Science ®Google Scholar
• Talan DA, Summanen PH, Finegold SM. Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse. Clin Infect Dis 2000;31:464-71
   PubMed Web of Science ®Google Scholar
• Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994;18:683-93
   PubMed Web of Science ®Google Scholar
• Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt) 2005;6:27-40
   PubMedGoogle Scholar
• Hemsell DL, Heard MC, Hemsell PG, et al. Sulbactam/ampicillin versus cefoxitin for uncomplicated and complicated acute pelvic inflammatory disease. Drugs 1988;35(Suppl 7):39-42
   PubMedGoogle Scholar
• McGregor JA, Crombleholme WR, Newton E, et al. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 1994;83:998-1004
   PubMed Web of Science ®Google Scholar
• Martens MG, Faro S, Hammill HA, et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of post-cesarean section endometritis. Diagn Microbiol Infect Dis 1989;12(Suppl 4):189S-94S
   PubMed Web of Science ®Google Scholar
• Martens MG, Faro S, Hammill HA, et al. Ampicillin/sulbactam versus clindamycin in the treatment of postpartum endomyometritis. South Med J 1990;83:408-13
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines; 2002
   Google Scholar
• Kosseim M, Ronald A, Plummer FA, et al. Treatment of acute pelvic inflammatory disease in the ambulatory setting: trial of cefoxitin and doxycycline versus ampicillin-sulbactam. Antimicrob Agents Chemother 1991;35:1651-6
   PubMed Web of Science ®Google Scholar
• Allen DM, Hartman BJ. Acinetobacter species. In: Mandell GL, Bennett JE, Dolin R, editors, Mandell, Douglas and Bennett's principles and practice of infectious disease, 6th edition. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 2632-6
   Google Scholar
• Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 2004;38:1449-59
   PubMed Web of Science ®Google Scholar
• Rafailidis PI, Ioannidou EN, Falagas ME. Ampicillin/sulbactam: current status in severe bacterial infections. Drugs 2007;67:1829-49
   PubMed Web of Science ®Google Scholar
• Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-51
   PubMed Web of Science ®Google Scholar
• Cisneros JM, Reyes MJ, Pachon J, et al. Bacteremia due toAcinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;22:1026-32
   PubMed Web of Science ®Google Scholar
• Traub WH, Spohr M. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A.baumannii, A. haemolyticus, genospecies 3, and genospecies 6. Antimicrob Agents Chemother 1997;33:1617-19
   Google Scholar
• Wang FD, Lin ML, Lee WS. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria. Int J Antimicrob Agents 2004;23:590-595
   PubMed Web of Science ®Google Scholar
• Levin AS, Levy CE, Manrique AE, et al. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003;21:58-62
   PubMed Web of Science ®Google Scholar
• Corbella X, Ariza J, Ardanuy C, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998;42:793-802
   PubMed Web of Science ®Google Scholar
• Wood GC, Hanes SD, Croce MA, et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34:1425-30
   PubMed Web of Science ®Google Scholar
• Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology, resistance and outcomes of Acinetobacter baumannii becteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001;21:142-8
   PubMed Web of Science ®Google Scholar
• Smolyakov R, Borer A, Riesemberg K, et al. Nosokomial multi-dryg resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. J Hosp Infect 2003;54:32-8
   PubMed Web of Science ®Google Scholar
• Oliveira MS, Prado GV, Costa SF, et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008;61:1369-75
   PubMed Web of Science ®Google Scholar
• Koklu S, Koksal AS, Asil M, et al. Probable sulbactam/ampicillin-associated prolonged cholestasis. Ann Pharmacother 2004;38:2055-8
   PubMed Web of Science ®Google Scholar
• Chamberlain A, White S, Bawdon R, et al. Pharmacokinetics of ampicillin and sulbactam in pregnancy. Am J Obstet Gynecol 1993;168:667-73
   PubMed Web of Science ®Google Scholar
• Wilson JT, Brown RD, Cherek DR, et al. Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences. Clin Pharmacokinet 1980;5:1-66
   PubMed Web of Science ®Google Scholar
• Arguello A. An open non-comparative pilot study of the safety and efficacy of oral sultamicillin in the treatment of mild to moderate upper respiratory tract infections in children. J Int Med Res 1992;20(Suppl 1):24A-30A
   PubMed Web of Science ®Google Scholar
• Biolcati AH. An open comparative study of the efficacy and safety of sultamicillin versus cefaclor in the treatment of acute otitis media in children. J Int Med Res 1992;20(Suppl 1):31A-43A
   PubMed Web of Science ®Google Scholar
• Chan KH, Bluestone CD, Tan LS, et al. Comparative study of sultamicillin and amoxicillin-clavulanate: treatment of acute otitis media. Pediatr Infect Dis J 1993;12:24-8
   PubMed Web of Science ®Google Scholar